We distribute our research widely to institutional and retail investors through various channels, including our proprietary database, website, and other platforms (such as Bloomberg, Refinitiv and Factset).
We are fully MiFID II compliant. Our research is paid for by our corporate clients, and we do not carry out any execution business.
Published reports can be obtained by searching our Research Library below, or directly from our Featured Companies page.
Scancell
FDA clears global Phase III trial for iSCIB1+Avacta
pre|CISION prospects buildHUTCHMED
A month of notable pipeline progressAvacta
FAP-Dox Phase Ib results confirm efficacy in SGCOxford BioDynamics
FY25 results: delivering despite the challengesHUTCHMED
Pipeline potential underpins long-term growth prospectsScancell
Latest SCOPE data confirm durable improvementScancell
Abundant development opportunities in immuno-oncologyOxford BioDynamics
£7m fundraise secures near-term futureAvacta
FAP-Dox cardiotox impresses; crucial £16m fundraise